Cargando…
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia
Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL). Thus, there is ongoing demand for novel agents. Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stage. CDK9 mediating RNA transcriptional elongation i...
Autores principales: | Göthert, Joachim R., Imsak, Roze, Möllmann, Michael, Kesper, Stefanie, Göbel, Maria, Dührsen, Ulrich, Scholz, Arne, Lücking, Ulrich, Baumann, Matthias, Unger, Anke, Schultz-Fademrecht, Carsten, Klebl, Bert, Eickhoff, Jan, Choidas, Axel, Dürig, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995184/ https://www.ncbi.nlm.nih.gov/pubmed/29899864 http://dx.doi.org/10.18632/oncotarget.25293 |
Ejemplares similares
-
Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia
por: Johansson, Patricia, et al.
Publicado: (2020) -
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
por: Lücking, Ulrich, et al.
Publicado: (2017) -
CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivo
por: Dampmann, Maria, et al.
Publicado: (2020) -
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia
por: Johansson, Patricia, et al.
Publicado: (2018) -
Deorphanization and characterization of the ectopically expressed olfactory receptor OR51B5 in myelogenous leukemia cells
por: Manteniotis, S, et al.
Publicado: (2016)